Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Manfredi

Showing results (61-70 of 140) with videos related to

Pageof 14
Sort By:
Expert Review of Gastroenterology & Hepatology|October 22, 2024
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinomaBernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, et al.
JHEP Reports : Innovation in Hepatology|December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN studyPasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
JAMA Oncology|July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.
Journal of Hepatology|November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Physical Review Letters|June 13, 2002
Measurement of the B0-B-0 oscillation frequency with inclusive dilepton eventsB Aubert, D Boutigny, J-M Gaillard, et al.
Physical Review Letters|August 23, 2002
Measurement of the branching fraction and CP content for the decay B0-->D(*+)D(*-)B Aubert, D Boutigny, J-M Gaillard, et al.
Physical Review Letters|August 26, 2003
Rare B decays into states containing a J/psi meson and a meson with s(-)s quark contentB Aubert, D Boutigny, J-M Gaillard, et al.
Pageof 14

Showing results (61-70 of 140) with videos related to

Sort By:
Pageof 14
Expert Review of Gastroenterology & Hepatology|October 22, 2024
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinomaBernardo Stefanini, Giulia F Manfredi, Antonio D'Alessio, et al.
JHEP Reports : Innovation in Hepatology|December 1, 2025
Lenvatinib <i>vs.</i> sorafenib as second-line treatment post atezolizumab plus bevacizumab for hepatocellular carcinoma: The LEVIATHAN studyPasquale Lombardi, Jung Sun Kim, Giulia F Manfredi, et al.
JHEP Reports : Innovation in Hepatology|January 29, 2025
Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumabMeng Wu, Claudia A M Fulgenzi, Antonio D'Alessio, et al.
JHEP Reports : Innovation in Hepatology|February 12, 2026
Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real studyCiro Celsa, Tiziana Pressiani, Naoshi Nishida, et al.
Hepatology (Baltimore, Md.)|July 19, 2024
Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatmentCiro Celsa, Giuseppe Cabibbo, Claudia Angela Maria Fulgenzi, et al.
JAMA Oncology|July 18, 2024
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D'Alessio, et al.
Journal of Hepatology|November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumoursCiro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Physical Review Letters|June 13, 2002
Measurement of the B0-B-0 oscillation frequency with inclusive dilepton eventsB Aubert, D Boutigny, J-M Gaillard, et al.
Physical Review Letters|August 23, 2002
Measurement of the branching fraction and CP content for the decay B0-->D(*+)D(*-)B Aubert, D Boutigny, J-M Gaillard, et al.
Physical Review Letters|August 26, 2003
Rare B decays into states containing a J/psi meson and a meson with s(-)s quark contentB Aubert, D Boutigny, J-M Gaillard, et al.
Pageof 14